Amboss, the Berlin-based ‘Medtech’ startup that offered a learning app for students but has turned to a knowledge platform for medical professionals, has raised €30 million in Series B funding.

The round is driven by Partech’s growth fund, with Target Global representing as a co-investor. 

Prior investors, like Cherry Ventures, Wellington Partners and Holtzbrinck Digital, also joined.

Who is Amboss?

Started in 2014 as a study program for medical students, Amboss has since grown to offer what it claims is the “most extensive and technologically-advanced” learning platform for medical students. 

It has been formed by a group of 70 doctors and 40 software engineers who run together in small cross-functional teams.

Amboss co-CEO Benedikt Hochkirchen says that medical students are still trained to remember facts, which become outdated quickly.

 Amboss’ “smart learning” technology declares to help students gain higher scores in their medical exams. It also promotes their contextual opinion to be better equipped for clinical practice.

Hochkirchen further mentioned that in a clinical study, doctors would change 50% of their decisions if they had the latest and accurate knowledge at hand.

In present life on the wards, doctors lack time to research and find the appropriate knowledge. 

For them, Amboss’ smart direction app is there to give instant, useful and reliable medical knowledge to carry out the best possible care.

Amboss co-CEO says the result is that the startup’s app lessens the average study time required for doctors to make a clinical decision from 30 minutes to 30 seconds. 

Crucially, its information base includes the most current medical facts and guidelines in every case.

Hochkirchen adds that young doctors have to obtain over a lot of responsibility early in their career.

Career starters are usually the first touchpoint with a doctor when a patient comes to a hospital. 

Amboss Medical Platform Mobile App Dashboard | iTMunch

The Need For Amboss

Regularly young doctors do not feel suitably prepared for the real-life challenges in those situations. 

Amboss is the source of opportunity to master those decisions, e.g. with emergency algorithms and lead symptoms.

Supplied with new capital, Amboss says it will stimulate the global rollout of its product with a focus on the U.S. 

Also, the startup will moreover develop its product, for both generalist and professional doctors, to help enhance their daily clinical decision-making.

SEE ALSO: App income scales 23% every year to $21.9B in Q3

For more updates and the latest tech news, keep reading iTMunch.